Aug 20, 2026 earnings call — Global push for hematology commercialization
Total revenue grew to $44.5 million, up 29% year-over-year, and the company reaffirmed cash runway through the end of 2027.
Revenue $0.0B (est $0.0B) · EPS $-1.28 (est $0.02)
Key quotes
"Importantly, and playing a role to achieving our global strategic objectives, we strengthened our leadership with the appointment of Dr. Faical as Chief Business Officer; and Mr. Jim Ziegler as Chief Commercial Officer."
"A lisaftoclax was approved in July last year for the treatment of adult patients with CLL/SLL, who have previously received at least 1 systemic therapy, including BTK inhibitors."
"Olverembatinib, our third-generation BCR-ABL inhibitor have been approved, CML-CP in China since 2021."
Analyst Q&A 9
NRDL listing progress in China
Q (Lut Ming Cheng · JPMorgan): Analyst asked about NRDL listing progress for lisaftoclax in China and when the next update will come.
A: They said lisaftoclax passed the initial review and is on the final NRDL expert review list. Management expects meetings later this month or early September and is confident NRDL coverage will be granted, though final price remains a concern.
"I think currently, as update, we have passed the initial review." — Dajun Yang (CEO·CHAIR)
Global trial enrollment status
Q (Yifan Zhai): Analyst wanted enrollment status for global registrational trials like POLARIS-1 and GLORA series and timing to NDA filing.
A: They said the global registrational teams are working hard and enrollment is on plan. GLORA-2 enrollment is complete, GLORA-3 is very close, and GLORA-4 and POLARIS studies should finish enrollment by late this year or early next year.
POLARIS trial timing and NDA plan
Q (Biren Amin · Piper Sandler): Analyst asked when to expect data from POLARIS-1 and POLARIS-2 and timing for NDA.
A: They said they are actively enrolling and expect to complete enrollment by the end of this year or early next year. They plan to submit the NDAs next year, with POLARIS-2 using a 6-month MMR endpoint and POLARIS-1 using a 3-month MRD-negative CR endpoint for FDA filing.
Takeda option, China hospital reach, ASH timing
Q (Yifan Zhai · Piper Sandler): Analyst asked when Takeda will decide on its option for olverembatinib, progress toward 2,000 hospitals in China, and whether APG-3288 data could appear at ASH and be tested in MS.
A: They described the Takeda option agreement signed in 2024 with upfront and potential milestone payments and tiered royalties. They said China commercial team is growing toward ~400 to cover 80% of the market and reach ~2,000 hospitals. For APG-3288, Phase I is in dose escalation and not expected at ASH; an EHA update next year is possible and INDs for autoimmune (including MS) are being prepared.
How olverembatinib differs from rivals
Q (Biren Amin · U.S. Bancorp BTIG): Analyst asked how to set expectations for POLARIS/GLORA readouts and what differentiates olverembatinib on efficacy and safety versus competitors.
A: They said preclinical data show olverembatinib is likely the most potent against T315I and compound mutations and active across a wide spectrum of mutations found in late-line CML. They noted regulatory and trial design constraints (Project Optimus) require randomized trials, and their goal is to give a strong inhibitor earlier to achieve deeper responses.
lisaftoclax vs competitors and pipeline priority
Q (Jeet Mukherjee · Truist): Analyst asked if lisaftoclax competes directly with sonrotoclax and how the 5-day ramp-up helps, and how the company prioritizes other programs.
A: They said lisaftoclax’s daily dosing and shorter half-life give better safety, tolerance and lower DDI risk versus other Bcl-2 agents, which matters for chronic leukemia patients and combinations. On prioritization, they said decisions are data-driven; several early programs (EED inhibitor, BTK degrader) look promising and resources are sufficient to advance multiple assets while focusing on the two approved products and global registrational trials.
venetoclax-failure strategy and study endpoints
Q (Gregory Renza · B. Riley): Analyst asked how quickly they can generate data in venetoclax-failure patients, expectations for GLORA-4 (CR/TLS/OS), POLARIS-2 powering and crossover, and OpEx trajectory.
A: They said preclinical and preliminary data show lisaftoclax plus olverembatinib can overcome venetoclax resistance and they are enrolling ven-failure patients globally. For GLORA-4, as a double-blind randomized study they cannot analyze early and will use CRi as the primary endpoint with OS maturing next year. POLARIS-2 allows crossover and uses the 24-week MMR as primary; they also said OpEx is at peak due to heavy enrollment but cash runway supports planned NDAs and data.
POLARIS-2 design details
Q (Mayank Mamtani · B. Riley): Analyst asked specifically about POLARIS-2 powering, how MMR rates are handled over time, and control arm crossover options.
A: They said FDA initially denied crossover but later allowed it, making the study more attractive. The POLARIS-2 primary endpoint is the 24-week MMR rate, the study is powered to show roughly double the MMR rate versus control, and POLARIS-2 includes a 2:1 randomization and a separate single-arm T315I cohort of 48 patients within the 333 total.
OpEx, cash runway, fundraising flexibility
Q (Yifan Zhai · Rodman & Renshaw): Analyst asked about capital allocation, whether they feel urgency to seek partnerships or other funding given burn and competition.
A: They said spending is prioritized to align with major milestones and the dual listing gives flexibility and optionality for raising capital or partnerships. Management reiterated cash runway supports R&D through the end of 2027 and they remain open to partnerships and other financing options as needed.